Cotinga Pharmaceuticals VE/BAIIA

Quel est le VE/BAIIA de Cotinga Pharmaceuticals?

Le VE/BAIIA de Cotinga Pharmaceuticals, Inc. est N/A

Quelle est la définition de VE/BAIIA?



VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

VE/BAIIA des entreprises dans Health Care secteur sur TSXV par rapport à Cotinga Pharmaceuticals

Que fait Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Entreprises avec ve/baiia similaire à Cotinga Pharmaceuticals